Molecular Glue Degrader–Induced Co-Degradation of Mutant KRAS & CRAF Drives In Vivo Responses

• Discovery and optimization of a molecular glue degrader targeting mutant KRAS and CRAF
• Mechanism of action and structural basis of induced co-degradation
• In vivo efficacy and therapeutic potential in KRAS-mutant models

Speakers:

Anita Bellail

Chief Executive Officer

HB Therapeutics, Inc.